Quantifying Effector Functions of Anti-HIV IgG1 Antibodies In Vivo.

体内量化抗 HIV IgG1 抗体的效应器功能。

• 批准号: 10078502
• 负责人: DAVID D HO
• 金额: $ 61.45万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10078502
• 关键词: Quantifying; Effector; Functions; Anti; HIV

PROJECT SUMMARY/ABSTRACT There is an abundance of evidence demonstrating the importance of Fc-mediated effector function to the overall activity of an antibody in vivo. However, the relative contribution of virus neutralization versus effector functions to the antiviral effect of an antibody remains undefined. We have proposed a series of experiments that will quantify the contributions of Fc-mediated effector functions to the overall activity of an antibody. The quantitative experiments will be performed in the setting of antibody treatment of SHIV infection in rhesus macaques. These fundamental questions in immunology have yet to be answered, and the resultant information promises to provide important insights on how the two major properties (neutralization versus effector functions) of a vaccine- induced IgG response combine forces to ward off the establishment of HIV infection.

项目概要/摘要 有大量证据表明 Fc 介导的效应器功能对整体的重要性 抗体在体内的活性。然而，病毒中和与效应功能的相对贡献 抗体的抗病毒作用仍不确定。我们提出了一系列实验 量化 Fc 介导的效应功能对抗体整体活性的贡献。定量 实验将在恒河猴 SHIV 感染的抗体治疗中进行。这些 免疫学中的基本问题尚未得到解答，由此产生的信息有望 提供有关疫苗的两个主要特性（中和作用与效应器功能）如何发挥作用的重要见解 诱导的 IgG 反应联合起来阻止 HIV 感染的建立。